NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
school
University Rankings
subject
University Subject Rankings
place
Country Rankings
insights
i10 Productivity Rankings
insights
Subject Rankings
format_list_numbered
Top 100 Scientists
format_list_numbered
Citation Rankings
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Ajlan Atasoy
AD Scientific Index 2024
Medical and Health Sciences / Medical Oncology
BioNTech - / Germany
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Ajlan Atasoy's MOST POPULAR ARTICLES
1-)
Osimertinib in Resected EGFR-Mutated Non–Small-Cell Lung CancerYL Wu, M Tsuboi, J He, T John, C Grohe, M Majem, JW Goldman, ...New England Journal of Medicine 383 (18), 1711-1723, 20208492020
2-)
Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR-mutated NSCLCYL Wu, T John, C Grohe, M Majem, JW Goldman, SW Kim, T Kato, ...Journal of Thoracic Oncology 17 (3), 423-433, 2022962022
3-)
Safety of nivolumab plus low‐dose ipilimumab in previously treated microsatellite instability‐high/mismatch repair‐deficient metastatic colorectal cancerMA Morse, MJ Overman, L Hartman, T Khoukaz, E Brutcher, HJ Lenz, ...The oncologist 24 (11), 1453-1461, 20191002019
4-)
Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR …HJJ Lenz, E Van Cutsem, ML Limon, KY Wong, A Hendlisz, M Aglietta, ...Annals of oncology 29, viii714, 2018972018
5-)
Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update.HJ Lenz, S Lonardi, V Zagonel, E Van Cutsem, ML Limon, KYM Wong, ...Journal of Clinical Oncology 38 (4_suppl), 11-11, 2020652020
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept